AIM ImmunoTech (AIM) Return on Capital Employed (2011 - 2026)
AIM ImmunoTech's (AIM) quarterly Return on Capital Employed came in at 989.02% in Q1 2026, down 174392.0% YoY from N/an in Q1 2025, and down 149.69% on a QoQ basis from 1990.44% in Q4 2025.
AIM ImmunoTech (AIM) Return on Capital Employed (2011 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 15 years of Return on Capital Employed data on file, last reported at 989.02% in Q1 2026.
- Quarterly Return on Capital Employed fell 174392.0% year-over-year to 989.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 989.02% (down 174392.0% YoY) and the FY2025 annual result came in at 1201.24%, down 75787.0% from the prior year.
- Return on Capital Employed slipped to 989.02% in Q1 2026, from 1990.44% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 1990.44% in Q4 2025 to a low of 1895.51% in Q3 2025.
- A 5-year average of 185.73% and a median of 66.86% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed jumped 325545 bps — and 2026, when it sank 174392 bps.
- Tracing AIM's Return on Capital Employed over 5 years: stood at 47.41% in 2022, then tumbled by 350 bps to 213.22% in 2023, then plunged by 493 bps to 1265.0% in 2024, then surged by 257 bps to 1990.44% in 2025, then tumbled by 150 bps to 989.02% in 2026.
- The last three Return on Capital Employed figures came in at 989.02% (Q1 2026), 1990.44% (Q4 2025), and 1895.51% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | -194.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -194.99% |
| Mar 31, 2026 | -989.02% |
| Dec 31, 2025 | 1,990.44% |
| Sep 30, 2025 | -1,895.51% |
| Jun 30, 2025 | 319.13% |
| Mar 31, 2025 | 754.90% |
| Dec 31, 2024 | -1,265.00% |
| Sep 30, 2024 | -613.45% |
| Jun 30, 2024 | -444.29% |
| Mar 31, 2024 | -421.75% |
| Dec 31, 2023 | -213.22% |
| Sep 30, 2023 | -90.19% |
| Jun 30, 2023 | -66.86% |
| Mar 31, 2023 | -56.73% |
| Dec 31, 2022 | -47.41% |
| Sep 30, 2022 | -47.74% |
| Jun 30, 2022 | -37.58% |
| Mar 31, 2022 | -33.07% |
| Dec 31, 2021 | -31.54% |
| Sep 30, 2021 | -25.79% |